Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
First publishedAug 5, 10:57 UTC
Last updatedAug 5, 13:35 UTC · 8m ago
1 outlet
CNBC Top News1 outlet
MarketWatch
2 outlets over time — hover a bar for its window & outletslast updated
Answer
Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
Reported by 2 outlets — MarketWatch, CNBC Top News. See all sources ↓
Read the full report at MarketWatch ↗
Why it matters
2 outlets are covering this world story — one to watch as reporting develops.
In brief
- What's the story?
- Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
- How widely is it covered?
- 2 outlets, average source rating 7.0/10.
- When was it last updated?
- 8m ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Lilly’s revenue soars 48%, driven by demand of its GLP-1s
Sources1TypeCoverage - Coverage card1 outlet2CoverageScouting report
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Sources1TypeCoverage
Related in the knowledge graph
Sources (2)
Avg source rating 7.0/10Processing cluster
A1A2A3B1B2B3